Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

n Therapeutics. "We are also very pleased with the safety profile demonstrated by Contrave thus far. We look forward to the results from the remaining Phase 3 trials which will further examine the efficacy, safety and tolerability of Contrave with less intensive behavior modification as well as in patients with Type 2 diabetes patients."

Patient enrollment has been completed in the three other Phase 3 trials. Orexigen expects to announce top-line results from these trials in mid-2009 and, pending additional positive results, submit a New Drug Application (NDA) with the FDA in late 2009.

Study Details and Results

The objective of this NB-302 trial was to determine the additional weight loss and health benefits of Contrave when added to an intensive diet and exercise program. The trial included the most intensive behavior modification regimen of the Phase 3 program for Contrave, which resulted, as expected, in a high degree of weight loss among placebo patients.

This 56-week, double-blind, placebo-controlled trial conducted at nine U.S. centers evaluated the efficacy and safety of Contrave (32mg naltrexone SR/360mg bupropion SR) compared to placebo in 793 obese patients who participated in an intense behavioral program consisting of counseling, diet and exercise. Patients enrolled in the trial were randomized on a 3 to 1 ratio between Contrave and placebo, and had a body mass index (BMI) of 30 to 45, or as low as 27 in the presence of cardiometabolic co-morbidities. Drug dosages were initially titrated over a four week period and then administered over 52 weeks of therapy at full dose. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

    Efficacy results from this trial are summarized in the following table:

                          Intent-To-Treat*            
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... at Indiana University Bloomington have described the self-assembly ... development with potential value for the field of ... photovoltaic cells. , Their paper, "Anion-Induced Dimerization of ... 2D Self-Assembled Crystals," has been published online by ... Royal Society of Chemistry. It is the first ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® ... bearings are uniquely suited to prevent loss of lubrication ... the high temperatures . , Recently, a manufacturer ... engineers at Graphite Metallizing to overcome problems with movement ... operation, pans containing blocks of powder mixture are loaded ...
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
(Date:7/31/2014)... Held at the Stanford Cancer Center, ... of the disease and its treatment. Survivors will find ... well as updates on the state-of-the-art with respect to ... for organizing this educational opportunity,” says KCA CEO Bill ... her colleagues have put together a program that balances ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Dialysis Corporation,of America (Nasdaq: DCAI ) announced today ... on May 7, 2008, after the close of the,market. ... conjunction with,its first quarter 2008 earnings release the following ... interested in participating in the May 8, 2008 conference ...
... 25 Processes and products based on,biomass and ... industry in a wide range of applications such ... of industrial,biotechnology in Germany will be held at ... 27-30, 2008) in Chicago, Illinois.,The panel runs from ...
... Leader Discusses Pioneer Hi-Bred Biotechnology Leadership ... at Beijing ... ),partnerships with China,s public and private sectors will help increase,farm productivity ... William S. Niebur, vice president -- DuPont Crop,Genetics Research and Development, ...
Cached Biology Technology:Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2DuPont Partnering with China to Increase Farm Productivity 2DuPont Partnering with China to Increase Farm Productivity 3
(Date:7/31/2014)... flowers- they are an iconic symbol of tropical ... the landscape. Some, like Hawaii,s State Flower- ... a relatively few botanists and Hawaiian conservation workers, ... intriguing related group of plants known as ... of Hibiscus species are in fact highly endangered. ...
(Date:7/31/2014)... Conn. , July 31, 2014 ... the growing m-commerce market, reminds investors and consumers ... smart wallet, Wocket™, that it will be on-air today, ... secure Wocket smart wallet will be featured in ... oriented television show that airs on the History ...
(Date:7/30/2014)... truffle uses reversible epigenetic processes to regulate its genes, ... - a picture of the genome regulation taking place ... journal Genome Biology and illustrates how the ... ,jumping genes,. The authors say this may shed light ... , Black truffles (Tuber melanosporum), also known as Prigord ...
Breaking Biology News(10 mins):Brother of Hibiscus is found alive and well on Maui 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3How black truffles deal with the jumpers in their genome 2
... synthetic life forms are at risk of being unduly ... are brought into the 21st century, an expert from The ... ANU College of Law takes a broad look at the ... biological inventions in his new book and the prognosis ...
... N.C. A small group of patients with a ... with an injectable microfoam experienced no neurological, visual or ... to preliminary results from a phase II trial. The ... D.C., at the annual scientific meeting of the Society ...
... CITY Two major eye diseases and leading causes of ... even prevented by drugs that activate a protein found ... Utah School of Medicine and several other institutions have ... diseases was prevented and even reversed when the protein, ...
Cached Biology News:Biotechnology needs 21st century patent system: Expert 2Improved foam for varicose veins found to be safe in preliminary results from phase II trial 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: